| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $5,331,108 | 10 | 100 |
| Goldan Keith A. | Chief Financial Officer | 0 | $0 | 3 | $136,988 | $-136,988 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 0 | $0 | 2 | $1.18M | $-1.18M |
| Metzger Michael A | Chief Executive Officer | 0 | $0 | 5 | $4.01M | $-4.01M |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Over the last 12 months, insiders at Syndax Pharmaceuticals, Inc. have bought $0 and sold $5.33M worth of Syndax Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syndax Pharmaceuticals, Inc. have bought $133,467 and sold $12.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $44,950 was made by Huber Martin H. Jr. (director) on 2025‑05‑19.
| 2026-07-08 | Sale | Metzger Michael A | Chief Executive Officer | 32,375 0.0361% | $24.24 | $784,776 | -18.04% | |
| 2026-06-12 | Sale | Botwood Nicholas A.J. | Head of R&D, CMO | 31,235 0.0357% | $18.14 | $566,603 | +10.30% | |
| 2026-06-11 | Sale | Botwood Nicholas A.J. | Head of R&D, CMO | 34,280 0.0389% | $18.00 | $617,040 | +12.23% | |
| 2026-06-01 | Sale | Metzger Michael A | Chief Executive Officer | 6,847 0.0078% | $18.99 | $130,025 | +5.68% | |
| 2026-06-01 | Sale | Goldan Keith A. | Chief Financial Officer | 1,177 0.0013% | $18.99 | $22,351 | +5.68% | |
| 2026-02-09 | Sale | Metzger Michael A | Chief Executive Officer | 17,159 0.0196% | $21.03 | $360,819 | -2.24% | |
| 2026-02-09 | Sale | Goldan Keith A. | Chief Financial Officer | 3,410 0.0039% | $21.03 | $71,705 | -2.24% | |
| 2026-02-06 | Sale | Metzger Michael A | Chief Executive Officer | 7,412 0.0084% | $20.62 | $152,835 | -1.24% | |
| 2026-02-06 | Sale | Goldan Keith A. | Chief Financial Officer | 2,082 0.0024% | $20.62 | $42,931 | -1.24% | |
| 2025-09-08 | Sale | Metzger Michael A | Chief Executive Officer | 157,307 0.1836% | $16.41 | $2.58M | +24.13% | |
| 2025-08-18 | Sale | Podlesak Dennis | director | 19,200 0.0222% | $15.84 | $304,170 | +27.47% | |
| 2025-08-15 | Sale | Podlesak Dennis | director | 19,200 0.022% | $15.54 | $298,408 | +28.53% | |
| 2025-08-14 | Sale | Podlesak Dennis | director | 19,200 0.0215% | $14.19 | $272,521 | +37.34% | |
| 2025-07-16 | Sale | Metzger Michael A | Chief Executive Officer | 7,534 0.0088% | $9.29 | $69,953 | +115.14% | |
| 2025-07-16 | Sale | Goldan Keith A. | Chief Financial Officer | 1,296 0.0015% | $9.29 | $12,033 | +115.14% | |
| 2025-05-19 | Katkin Keith | director | 10,000 0.0114% | $9.11 | $91,120 | +83.33% | ||
| 2025-05-19 | Goldan Keith A. | Chief Financial Officer | 3,000 – | $0 | $0 | +83.33% | ||
| 2025-05-19 | Huber Martin H. Jr. | director | 5,000 0.0056% | $8.99 | $44,950 | +83.33% | ||
| 2025-05-16 | Botwood Nicholas A.J. | Head of R&D, CMO | 11,765 0.0136% | $8.99 | $105,826 | +86.91% | ||
| 2025-03-04 | Sale | Metzger Michael A | Chief Executive Officer | 7,814 0.0093% | $15.05 | $117,564 | +3.27% |
| Metzger Michael A | Chief Executive Officer | 484843 0.5472% | $9.97M | 0 | 29 | |
| Goldan Keith A. | Chief Financial Officer | 139252 0.1572% | $2.86M | 2 | 6 | <0.0001% |
| Botwood Nicholas A.J. | Head of R&D, CMO | 60885 0.0687% | $1.25M | 1 | 2 | +86.91% |
| ROYSTON IVOR | director | 750545 0.847% | $15.43M | 1 | 0 | <0.0001% |
| Podlesak Dennis | director | 191763 0.2164% | $3.94M | 1 | 4 | +23.96% |
| Katkin Keith | director | 100000 0.1129% | $2.06M | 1 | 2 | +83.33% |
| Gallagher Neil | President, Head of R&D | 85095 0.096% | $1.75M | 0 | 1 | |
| Huber Martin H. Jr. | director | 79000 0.0892% | $1.62M | 1 | 0 | +83.33% |
| Meury William | director | 48000 0.0542% | $986,880.00 | 0 | 1 | |
| Legault Pierre | director | 32000 0.0361% | $657,920.00 | 0 | 4 | |
| Morrison Briggs | director | 17836 0.0201% | $366,708.16 | 4 | 18 | +43.88% |
| Egros Fabrice | 16000 0.0181% | $328,960.00 | 0 | 4 | ||
| Meyers Michael L. | SVP, Chief Medical Officer | 15666 0.0177% | $322,092.96 | 3 | 0 | +40.96% |
| Ordentlich Peter | 0 0% | $0 | 0 | 9 | ||
| Nolte Alexander | 0 0% | $0 | 0 | 1 |
$8,217,280 | 112 | 46.33% | $1.68B | |
$1,376,668 | 53 | 18.46% | $2.06B | |
$530,111,731 | 35 | 8.69% | $1.57B | |
$28,907,358 | 35 | 41.41% | $1.97B | |
$38,398,021 | 25 | 24.88% | $2.07B | |
$4,431,947 | 22 | 36.10% | $1.6B | |
$135,656,796 | 20 | 30.67% | $1.68B | |
$24,007,605 | 16 | -20.65% | $1.79B | |
$154,554,190 | 14 | 29.60% | $1.98B | |
$48,220,484 | 14 | 2.13% | $1.78B | |
$108,588,651 | 14 | 29.35% | $1.71B | |
Syndax Pharmaceuticals, Inc. (SNDX) | $3,101,788 | 13 | 41.97% | $1.82B |
$278,247,340 | 12 | 58.08% | $1.92B | |
$5,794,001 | 10 | 23.26% | $2.02B | |
$94,976,497 | 10 | -10.72% | $1.92B | |
$47,238,722 | 7 | -23.48% | $1.78B | |
$1,011,808 | 4 | 52.60% | $1.68B | |
$103,599,972 | 2 | -36.81% | $1.9B | |
$23,993,224 | 1 | 9.82% | $1.84B |
| Increased Positions | 117 | +45.17% | 16M | +15.49% |
| Decreased Positions | 113 | -43.63% | 17M | -16.33% |
| New Positions | 33 | New | 6M | New |
| Sold Out Positions | 29 | Sold Out | 6M | Sold Out |
| Total Postitions | 263 | +1.54% | 100M | -0.83% |
| Blackrock, Inc. | $183,718.00 | 9.91% | 8.63M | -2M | -17.52% | 2025-09-30 |
| Kynam Capital Management, Lp | $181,476.00 | 9.79% | 8.52M | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $116,861.00 | 6.31% | 5.49M | -310,761 | -5.36% | 2025-09-30 |
| Vanguard Group Inc | $109,453.00 | 5.91% | 5.14M | +104,683 | +2.08% | 2025-09-30 |
| Point72 Asset Management, L.P. | $90,633.00 | 4.89% | 4.26M | +2M | +100% | 2025-09-30 |
| State Street Corp | $82,081.00 | 4.43% | 3.85M | +410,797 | +11.93% | 2025-09-30 |
| Bank Of America Corp /De/ | $78,762.00 | 4.25% | 3.7M | -141,119 | -3.68% | 2025-09-30 |
| Eversept Partners, Lp | $73,854.00 | 3.99% | 3.47M | -598,041 | -14.71% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $70,545.00 | 3.81% | 3.31M | +2M | +131.21% | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $53,250.00 | 2.87% | 2.5M | +400,000 | +19.05% | 2025-09-30 |